2021/2022 HCPCS Code Q2040

Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
Notice HCPCS Q2040 terminated on December 31, 2018.
Short Description Tisagenlecleucel car-pos t
HCPCS Coverage Code C = Carrier judgment
HCPCS Action Code N = No maintenance for this code
HCPCS Action Effective Date January 01, 2019
HCPCS Code Added Date January 01, 2018
HCPCS Termination Date December 31, 2018
HCPCS Pricing Indicator Code 51 = Drugs
HCPCS Multiple Pricing Indicator Code A = Not applicable as HCPCS priced under one methodology
HCPCS ASC Payment Group Code YY
HCPCS ASC Payment Group Effective Date January 01, 2018
HCPCS Type Of Service Code 1 = Medical care
HCPCS Anesthesia Base Unit Quantity 0